AbstractMicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa d...
Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tool...
MicroRNAs (miRNAs) have been recognized as significantly involved in prostate cancer (PCa). Since an...
Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even inadvanced ‘castrate-re...
AbstractMicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and met...
Background: Systematic approaches to functionally identify key players in microRNA (miRNA)-target ne...
MicroRNAs (miRNAs) are non-coding small RNAs that target mRNA to reduce protein expression. They pla...
Abstract MicroRNAs (miRNAs) are short non-coding RNAs that are involved in several important biologi...
Background: Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certai...
Dysregulation of miRNAs has been demonstrated in several human malignancies including prostate cance...
Prostate cancer (PCa) is the second most common cause of cancer-specific deaths in the U.S. Unfortun...
Prostate cancer is the second highest cause of cancer mortality after lung tumours. In USA it affect...
Background: Prostate cancer (PCa), a highly incident and heterogeneous malignancy, mostly affects me...
MicroRNAs (miRNAs) play important roles in cancer formation and progression by suppressing the produ...
MicroRNAs (miRNAs) have been recognized as significantly involved in prostate cancer (PCa). Since an...
Prostate cancer (PCa) as the second leading cause of cancer death in men in the Western world is of ...
Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tool...
MicroRNAs (miRNAs) have been recognized as significantly involved in prostate cancer (PCa). Since an...
Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even inadvanced ‘castrate-re...
AbstractMicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and met...
Background: Systematic approaches to functionally identify key players in microRNA (miRNA)-target ne...
MicroRNAs (miRNAs) are non-coding small RNAs that target mRNA to reduce protein expression. They pla...
Abstract MicroRNAs (miRNAs) are short non-coding RNAs that are involved in several important biologi...
Background: Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certai...
Dysregulation of miRNAs has been demonstrated in several human malignancies including prostate cance...
Prostate cancer (PCa) is the second most common cause of cancer-specific deaths in the U.S. Unfortun...
Prostate cancer is the second highest cause of cancer mortality after lung tumours. In USA it affect...
Background: Prostate cancer (PCa), a highly incident and heterogeneous malignancy, mostly affects me...
MicroRNAs (miRNAs) play important roles in cancer formation and progression by suppressing the produ...
MicroRNAs (miRNAs) have been recognized as significantly involved in prostate cancer (PCa). Since an...
Prostate cancer (PCa) as the second leading cause of cancer death in men in the Western world is of ...
Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tool...
MicroRNAs (miRNAs) have been recognized as significantly involved in prostate cancer (PCa). Since an...
Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even inadvanced ‘castrate-re...